Abstract
The present study was aimed at developing a sustained release formulation of Nimodipine (NIM) nanoparticles using the biodegradable polymers, poly (lactide-co-glycolide) (PLGA 50:50 and 85:15) as carrier. NIM is a widely used calcium channel blocker which has to be administered as an intravenous infusion for a prolonged period of 1-2 weeks in the treatment of cerebral vasospasm. A sustained release biodegradable formulation would serve to replace this conventional therapy of continuous intravenous administration. PLGA nanoparticles were prepared by a modified precipitation method using high pressure homogenizer at 10, 000 to 14,000 psi. A 32 factorial design was applied for optimization of the formulation parameters and for studying the effect of two independent variables [drug: polymer ratio and concentration of surfactant (Pluronic F 127)] on entrapment efficiency and mean particle size (response variables). Contour plots were plotted which gave a visual representation of the two variables on the dependent variables and also indicated nonlinear relationship between them. The nanoparticles had particle size of 131±1.9 nm for PLGA 50:50 and196±2.2 nm for PLGA 85:15. Scanning Electron Microscopy studies indicated that nanoparticles had spherical shape with a regular surface. The nanoparticles had high entrapment efficiency (96.42±2.09 % for PLGA 50:50 and 94.50±1.25 % for PLGA 85:15). DSC thermograms indicated that NIM was dispersed as an amorphous state in the nanoparticles. In vitro drug release from the lyophilized nanoparticles showed 94.35 ± 3.8 % NIM release from PLGA (50:50) nanoparticles and 63.32 ± 4.6 % release from PLGA (85:15) nanoparticles in 25 days. The release was first ordered and fickian diffusion kinetics in both the cases. These preliminary results indicate that NIM loaded PLGA nanoparticles could be effective in sustaining its release for a prolonged period. However, further studies are needed to confirm its performance in vivo.
Keywords: Nimodipine, PLGA, nanoparticles, 32 factorial design, sustained release
Current Drug Delivery
Title: Nimodipine Loaded PLGA Nanoparticles: Formulation Optimization Using Factorial Design,Characterization and In Vitro Evaluation
Volume: 4 Issue: 3
Author(s): Ashish K. Mehta, Khushwant S. Yadav and Krutika K. Sawant
Affiliation:
Keywords: Nimodipine, PLGA, nanoparticles, 32 factorial design, sustained release
Abstract: The present study was aimed at developing a sustained release formulation of Nimodipine (NIM) nanoparticles using the biodegradable polymers, poly (lactide-co-glycolide) (PLGA 50:50 and 85:15) as carrier. NIM is a widely used calcium channel blocker which has to be administered as an intravenous infusion for a prolonged period of 1-2 weeks in the treatment of cerebral vasospasm. A sustained release biodegradable formulation would serve to replace this conventional therapy of continuous intravenous administration. PLGA nanoparticles were prepared by a modified precipitation method using high pressure homogenizer at 10, 000 to 14,000 psi. A 32 factorial design was applied for optimization of the formulation parameters and for studying the effect of two independent variables [drug: polymer ratio and concentration of surfactant (Pluronic F 127)] on entrapment efficiency and mean particle size (response variables). Contour plots were plotted which gave a visual representation of the two variables on the dependent variables and also indicated nonlinear relationship between them. The nanoparticles had particle size of 131±1.9 nm for PLGA 50:50 and196±2.2 nm for PLGA 85:15. Scanning Electron Microscopy studies indicated that nanoparticles had spherical shape with a regular surface. The nanoparticles had high entrapment efficiency (96.42±2.09 % for PLGA 50:50 and 94.50±1.25 % for PLGA 85:15). DSC thermograms indicated that NIM was dispersed as an amorphous state in the nanoparticles. In vitro drug release from the lyophilized nanoparticles showed 94.35 ± 3.8 % NIM release from PLGA (50:50) nanoparticles and 63.32 ± 4.6 % release from PLGA (85:15) nanoparticles in 25 days. The release was first ordered and fickian diffusion kinetics in both the cases. These preliminary results indicate that NIM loaded PLGA nanoparticles could be effective in sustaining its release for a prolonged period. However, further studies are needed to confirm its performance in vivo.
Export Options
About this article
Cite this article as:
Ashish K. Mehta , Khushwant S. Yadav and Krutika K. Sawant , Nimodipine Loaded PLGA Nanoparticles: Formulation Optimization Using Factorial Design,Characterization and In Vitro Evaluation, Current Drug Delivery 2007; 4 (3) . https://dx.doi.org/10.2174/156720107781023929
DOI https://dx.doi.org/10.2174/156720107781023929 |
Print ISSN 1567-2018 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5704 |
Call for Papers in Thematic Issues
Advances of natural products, bio-actives and novel drug delivery system against emerging viral infections
Due to the increasing prevalence of viral infections and the ability of these human pathogens to develop resistance to current treatment strategies, there is a great need to find and develop new compounds to combat them. These molecules must have low toxicity, specific activity and high bioavailability. The most suitable ...read more
Electrospun Fibers as Drug Delivery Systems
In recent years, electrospun fibers have attracted considerable attention as potential platforms for drug delivery due to their distinctive properties and adaptability. These fibers feature a notable surface area-to-volume ratio and can be intentionally designed with high porosity, facilitating an increased capacity for drug loading and rendering them suitable for ...read more
Emerging Nanotherapeutics for Mitigation of Neurodegenerative Disorders
Conditions affecting the central nervous system (CNS) present a significant hurdle due to limited access of both treatments and diagnostic tools for the brain. The blood-brain barrier (BBB) acts as a barrier, restricting the passage of molecules from the bloodstream into the brain. The most formidable challenge facing scientists is ...read more
Nanotechnology Based Chemotherapy for the treatment of Head & Neck Cancer
The escalating recurrence rates observed in Head and Neck cancer, particularly within the chemo-therapeutically treated cohort (50-60%), can be attributed to the non-selective nature of current anticancer drug delivery modalities. In this context, nanotechnology-based drug delivery systems emerge as a promising avenue for achieving precise localization of therapeutic agents to ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Role of T and B Cells in Atherosclerosis: Potential Clinical Implications
Current Pharmaceutical Design Sestrins: A New Kid for Stroke Treatment?
Current Drug Delivery Antiplatelet Therapy and Oral Anticoagulation for Prevention of Ischemic Stroke
Current Drug Therapy Structural Development, Haematological Immunological and Pharmacological Effects of Quinolones
Recent Patents on Anti-Infective Drug Discovery Role of COL4A1 in Basement-Membrane Integrity and Cerebral Small-Vessel Disease. The COL4A1 Stroke Syndrome
Current Medicinal Chemistry Neurobiological Influences on Recovery from Traumatic Brain Injury: The Role of Genetic Polymorphisms
Current Pharmaceutical Design Advanced Therapies For End-Stage Heart Failure
Current Cardiology Reviews Omega-3 Nutrition Therapy for the Treatment of Diabetic Sensorimotor Polyneuropathy
Current Diabetes Reviews Effect of β-Blockers on Perioperative Myocardial Ischemia in Patients Undergoing Noncardiac Surgery
Current Drug Targets Safety Analysis and Improved Cardiac Function Following Local Autologous Transplantation of CD133+ Enriched Bone Marrow Cells After Myocardial Infarction
Current Neurovascular Research Visceral and Subcutaneous Adiposity: Are Both Potential Therapeutic Targets for Tackling the Metabolic Syndrome?
Current Pharmaceutical Design Matrix Metalloproteinases and Vulnerable Atheromatous Plaque
Current Topics in Medicinal Chemistry Unraveling the Action Mechanism of Buyang Huanwu Tang (BYHWT) for Cerebral Ischemia by Systematic Pharmacological Methodology
Combinatorial Chemistry & High Throughput Screening Virus-Associated Vasculitides: An Update
Current Immunology Reviews (Discontinued) Cerebrovascular Diseases in HIV-Infected Patients
Current HIV Research Assessment of Vascular Geometry for Bilateral Carotid Artery Ligation to Induce Early Basilar Terminus Aneurysmal Remodeling in Rats
Current Neurovascular Research Health Benefits of Honey: Implications for Treating Cardiovascular Diseases
Current Nutrition & Food Science Secondary Stroke Prevention in Patients with Cryptogenic Stroke and Patent Foramen Ovale
Vascular Disease Prevention (Discontinued) Structure Activity Relationships for Nicotinamide in the Treatment of Stroke
Letters in Drug Design & Discovery The Updated Role of the Blood Brain Barrier in Subarachnoid Hemorrhage: From Basic and Clinical Studies
Current Neuropharmacology